Adverse events, such as cytopenias in two patients (patients 14 and 34), psoriasis (patient 12), and APS-associated stroke (patient 40), could represent STAT3-GOF-related manifestations and rather reflect the incomplete efficacy of JAKi treatment. This evidence concerns the gene STAT3 and psoriasis.